公开(公告)号：US06790848B2

公开(公告)日：2004-09-14

申请号：US10172360

申请日：2002-06-14

申请人： Andrew John Briggs ,  Robin Douglas Clark ,  Ralph New Harris, III ,  David Bruce Repke ,  Douglas Leslie Wren

发明人： Andrew John Briggs ,  Robin Douglas Clark ,  Ralph New Harris, III ,  David Bruce Repke ,  Douglas Leslie Wren

IPC分类号： C07D40304

CPC分类号： C07D209/40

摘要： This invention relates to compounds which have generally 5-HT6 receptor affinity and which are represented by Formula I: wherein R3 is SO2—Ar, Ar is aryl or heteroaryl; and R1, R2, R4 and R5 are as defined herein; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and methods of preparation thereof.

摘要翻译： 本发明涉及通常具有5-HT 6受体亲和性并由式I表示的化合物：其中R 3是SO 2 -Ar，Ar是芳基或杂芳基; 且R 1，R 2，R 4和R 5如本文所定义; 或各异构体，异构体的外消旋或非外消旋混合物，或其药学上可接受的盐或溶剂合物。 本发明还涉及含有这些化合物的药物组合物，其用作治疗剂的方法及其制备方法。

公开(公告)号：US20130123251A1

公开(公告)日：2013-05-16

申请号：US13713484

申请日：2012-12-13

申请人： Jacob Berger ,  Robin Douglas Clark ,  Shu-Hai Zhao

发明人： Jacob Berger ,  Robin Douglas Clark ,  Shu-Hai Zhao

IPC分类号： C07D265/36

CPC分类号： C07D265/36 ,  C07D267/14 ,  C07D413/04 ,  C07D413/12

摘要： The present invention provides a compound of the formula: a pharmaceutically acceptable salt or a prodrug thereof, where R1, R2, R3, R4, R5, R6, R7, R8, R9, Y, Z1, m, n, and p are as defined herein. The present invention also provides compositions comprising, methods for using, and methods for preparing Compound of Formula I.

摘要翻译： 本发明提供下式的化合物：其药学上可接受的盐或前体药物，其中R1，R2，R3，R4，R5，R6，R7，R8，R9，Y，Z1，m，n和p为 本文定义。 本发明还提供了包含式I化合物的使用方法和方法的组合物。

公开(公告)号：US08377931B2

公开(公告)日：2013-02-19

申请号：US12584373

申请日：2009-09-04

申请人： Jacob Berger ,  Robin Douglas Clark ,  Shu-Hai Zhao

发明人： Jacob Berger ,  Robin Douglas Clark ,  Shu-Hai Zhao

IPC分类号： A61K31/535 ,  C07D265/38

CPC分类号： C07D265/36 ,  C07D267/14 ,  C07D413/04 ,  C07D413/12

摘要： The present invention provides a compound of the formula: a pharmaceutically acceptable salt or a prodrug thereof, where R1, R2, R3, R4, R5, R6, R7, R8, R9, Y, Z1, m, n, and p are as defined herein. The present invention also provides compositions comprising, methods for using, and methods for preparing Compound of Formula I.